US FDA recommends restricting Johnson & Johnson’s COVID-19 vaccine
Johnson & Johnson’s COVID-19 vaccine. Photo: Reuters
The US Food and Drug Administration (FDA) yesterday recommended, restricting injections vaccine against COVID-19 Janssen of Johnson & Johnson in adults due to the rare risk of thromboembolic events.
The FDA stated that the results of the study, evaluation, and analysis showed an increased risk of rare thrombocytopenia, accompanied by thrombocytopenia syndrome, about 1-2 weeks after receiving Janssen vaccine. Therefore, the FDA recommends limiting the use of this vaccine.
Johnson & Johnson’s Janssen COVID-19 vaccine was approved for emergency use in the US from February 27, 2021. As of March 18, there were 60 cases of thrombocytopenia syndrome, including 9 deaths.
Thrombocytopenia is a syndrome associated with low levels of platelets in the blood with the formation of blood clots. These blood clots can appear in many places in the body such as the brain or abdomen. To date, the mechanism underlying thrombosis is still unknown.
* Invite readers to watch the programs broadcast by Vietnam Television on TV Online and VTVGo!
at Blogtuan.info – Source: vtv.vn – Read the original article here